Halozyme Therapeutics, Inc. (HALO)

71.21 -0.61 (-0.85%) USD  |  NASDAQ  |  Jan 16, 16:00
71.20 -0.01 (-0.01%) After-Hours: 20:00
More

Halozyme Therapeutics Current Deferred Revenue (Per Share)

Current Deferred Revenue (Per Share) Chart

View Current Deferred Revenue (Per Share) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Current Deferred Revenue (Per Share) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Current Deferred Revenue (Per Share) Range, Past 5 Years

View Current Deferred Revenue (Per Share) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Current Deferred Revenue (Per Share) Benchmarks

View Current Deferred Revenue (Per Share) Benchmarks
Start Trial
Johnson & Johnson --
Merck & Co., Inc. --
AIM ImmunoTech, Inc. --
Stryker Corp. --
Skye Bioscience, Inc. --